ATE224918T1 - Zusammensetzung zur hemmung der thromboseentstehung - Google Patents

Zusammensetzung zur hemmung der thromboseentstehung

Info

Publication number: ATE224918T1
Authority: AT; Austria
Prior art keywords: thrombosis; clot; thrombin; compositions; thrombus
Prior art date: 1995-03-31

Application number

AT96302311T

Other languages

English (en)

Inventor

Jeffrey I Weitz

Jack Hirsh

Edward Young

Original Assignee

Hamilton Civic Hospitals Res

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-31

Filing date

1996-04-01

Publication date

2002-10-15

1995-10-06 Priority claimed from US08/540,324 external-priority patent/US5744457A/en

1996-04-01 Application filed by Hamilton Civic Hospitals Res filed Critical Hamilton Civic Hospitals Res

2002-10-15 Application granted granted Critical

2002-10-15 Publication of ATE224918T1 publication Critical patent/ATE224918T1/de

Links

208000007536 Thrombosis Diseases 0.000 title abstract 4
239000000203 mixture Substances 0.000 title abstract 4
230000015572 biosynthetic process Effects 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
108090000190 Thrombin Proteins 0.000 abstract 3
229960004072 thrombin Drugs 0.000 abstract 3
208000006011 Stroke Diseases 0.000 abstract 2
239000003795 chemical substances by application Substances 0.000 abstract 2
206010002388 Angina unstable Diseases 0.000 abstract 1
206010003178 Arterial thrombosis Diseases 0.000 abstract 1
206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
102000009123 Fibrin Human genes 0.000 abstract 1
108010073385 Fibrin Proteins 0.000 abstract 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical group CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
102000004032 Heparin Cofactor II Human genes 0.000 abstract 1
108090000481 Heparin Cofactor II Proteins 0.000 abstract 1
IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 abstract 1
208000010378 Pulmonary Embolism Diseases 0.000 abstract 1
208000007814 Unstable Angina Diseases 0.000 abstract 1
206010047249 Venous thrombosis Diseases 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
206010000891 acute myocardial infarction Diseases 0.000 abstract 1
125000003172 aldehyde group Chemical group 0.000 abstract 1
230000000747 cardiac effect Effects 0.000 abstract 1
238000000502 dialysis Methods 0.000 abstract 1
230000003292 diminished effect Effects 0.000 abstract 1
230000002526 effect on cardiovascular system Effects 0.000 abstract 1
229950003499 fibrin Drugs 0.000 abstract 1
229960002897 heparin Drugs 0.000 abstract 1
229920000669 heparin Polymers 0.000 abstract 1
230000000415 inactivating effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
239000003055 low molecular weight heparin Substances 0.000 abstract 1
229940127215 low-molecular weight heparin Drugs 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
- C08B37/0078—Degradation products

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Materials Engineering (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Polymers & Plastics (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT96302311T 1995-03-31 1996-04-01 Zusammensetzung zur hemmung der thromboseentstehung ATE224918T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41233295A	1995-03-31	1995-03-31
US48587295A	1995-06-07	1995-06-07
US08/540,324 US5744457A (en)	1995-03-31	1995-10-06	Compositions and methods for inhibiting thrombogenesis

Publications (1)

Publication Number	Publication Date
ATE224918T1 true ATE224918T1 (de)	2002-10-15

Family

ID=27410936

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96302311T ATE224918T1 (de)	1995-03-31	1996-04-01	Zusammensetzung zur hemmung der thromboseentstehung

Country Status (4)

Country	Link
EP (1)	EP0735050B1 (de)
AT (1)	ATE224918T1 (de)
DE (1)	DE69623840D1 (de)
GB (1)	GB2299998B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5767269A (en) *	1996-10-01	1998-06-16	Hamilton Civic Hospitals Research Development Inc.	Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics
WO1998055515A1 (en) *	1997-06-06	1998-12-10	Hamilton Civic Hospitals Research Development, Inc.	Modified low molecular weight heparin that inhibits clot associated coagulation factors
US6794412B1 (en)	1999-03-11	2004-09-21	Bristol-Myers Squibb Pharma Company	Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
CA2361650A1 (en) *	1999-03-11	2000-09-14	Dupont Pharmaceuticals Company	Treatment of thrombosis by combined use of a factor xa inhibitor and aspirin, tissue plasminogen activator (tpa), a gpiib/iiia antagonist, low molecular weight heparin or heparin
BR0010380A (pt) *	1999-03-11	2002-03-26	Du Pont Pharm Co	Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos
JP4828795B2 (ja)	2002-03-11	2011-11-30	モメンタファーマシューティカルズインコーポレイテッド	硫酸化多糖類の分析
US9139876B1 (en)	2007-05-03	2015-09-22	Momenta Pharmacueticals, Inc.	Method of analyzing a preparation of a low molecular weight heparin
US8592393B2 (en) *	2007-11-02	2013-11-26	Momenta Pharmaceuticals, Inc.	Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
US8569262B2 (en)	2007-11-02	2013-10-29	Momenta Pharmaceuticals, Inc.	Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
EP2205642B1 (de) *	2007-11-02	2016-01-27	Momenta Pharmaceuticals, Inc.	Nicht gerinnungshemmende polysaccharidzusammensetzungen
SG185925A1 (en) *	2007-11-02	2012-12-28	Momenta Pharmaceuticals Inc	Non-anticoagulant polysaccharide compositions
BR112012026542A2 (pt)	2010-04-16	2016-07-12	Momenta Pharmaceuticals Inc	abordagem seletiva de tecido
EP2582355A2 (de)	2010-06-17	2013-04-24	Momenta Pharmaceuticals, Inc.	Verfahren und zusammensetzungen zur förderung des haarwachstums
US9068957B2 (en)	2011-02-21	2015-06-30	Momenta Pharmaceuticals, Inc.	Evaluating heparin preparations
WO2013095215A1 (en) *	2011-12-19	2013-06-27	Dilaforette Ab	Low anticoagulant heparins
US9475888B2 (en) *	2011-12-19	2016-10-25	Dilafor Ab	Non anti-coagulative glycosaminoglycans comprising repeating disaccharide unit and their medical use
EP3003323A4 (de) *	2013-05-28	2016-12-28	Momenta Pharmaceuticals Inc	Polysaccharidzusammensetzungen und zugehörige verfahren
JP2016520613A (ja)	2013-05-28	2016-07-14	モメンタファーマシューティカルズインコーポレイテッド	薬学的組成物
GB2515315A (en)	2013-06-19	2014-12-24	Dilafor Ab	New Processes
GB202217216D0 (en) *	2022-11-17	2023-01-04	Bhogal Pervinder Singh	Preparation of medium molecular weight heparin
WO2025106117A1 (en) *	2023-11-17	2025-05-22	Glycos Biomedical Ltd.	Medium molecular weight heparin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1136620A (en) *	1979-01-08	1982-11-30	Ulf P.F. Lindahl	Heparin fragments having selective anticoagulation activity
US4916219A (en) *	1985-03-28	1990-04-10	University Of Iowa Research Foundation	Oligosaccharide heparin fragments as inhibitors of complement cascade
FR2614026B1 (fr) *	1987-04-16	1992-04-17	Sanofi Sa	Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
IE61565B1 (en) *	1988-08-24	1994-11-16	Akzo Nv	Heparin fragments and fractions with anti-HIV action
SE9002550D0 (sv) *	1990-08-01	1990-08-01	Kabivitrum Ab	Heparinfragment
FR2687158B1 (fr) *	1992-02-07	1995-06-30	Rhone Poulenc Rorer Sa	Polysaccharides sulfates, procede de preparation, composition pharmaceutique et utilisation.

1996
- 1996-04-01 AT AT96302311T patent/ATE224918T1/de not_active IP Right Cessation
- 1996-04-01 EP EP96302311A patent/EP0735050B1/de not_active Expired - Lifetime
- 1996-04-01 DE DE69623840T patent/DE69623840D1/de not_active Expired - Lifetime
- 1996-04-01 GB GB9606881A patent/GB2299998B/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GB2299998B (en)	1997-03-26
DE69623840D1 (de)	2002-10-31
GB9606881D0 (en)	1996-06-05
EP0735050A3 (de)	1997-01-22
GB2299998A (en)	1996-10-23
EP0735050B1 (de)	2002-09-25
EP0735050A2 (de)	1996-10-02

Legal Events

Date	Code	Title	Description
2003-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE224918T1 (de)	2002-10-15	Zusammensetzung zur hemmung der thromboseentstehung
WO1996029973A3 (en)	1996-12-19	Compositions and methods for inhibiting thrombogenesis
Lijnen et al.	1983	Heparin binding properties of human histidine-rich glycoprotein. Mechanism and role in the neutralization of heparin in plasma.
CA1136620A (en)	1982-11-30	Heparin fragments having selective anticoagulation activity
Klement et al.	2002	Blood-compatible biomaterials by surface coating with a novel antithrombin–heparin covalent complex
AU596951B2 (en)	1990-05-24	Blood coagulation inhibiting proteins, processes for preparing them and their uses
CA2084301C (en)	2005-10-25	Heparin derivatives and process for the preparation thereof
HK1045532A1 (zh)	2002-11-29	抑制与凝结有关凝结因子的肝素成份
Haverkate et al.	1979	Anticlotting properties of fragments D from human fibrinogen and fibrin
US8071570B2 (en)	2011-12-06	Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JPS60135401A (ja)	1985-07-18	デキストラン誘導体
Dryjski et al.	1983	Effect of glycosaminoglycans and antithrombin III on uptake and inhibition of thrombin by the vascular wall
Budzynski et al.	1979	The interference of plasmic degradation products of human crosslinked fibrin with clot formation
Patel et al.	2007	Covalent antithrombin–heparin complexes
Ku et al.	1983	Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin.
DE60039437D1 (de)	2008-08-21	Verwendung der sulfatierten polysacchariden zur behandlung von thrombosen
Godal	1961	The influence of heparin on the fibrin clot
Nader et al.	1989	Structural requirements of heparin disaccharides responsible for hemorrhage: reversion of the antihemostatic effect by ATP
Tarvady et al.	1987	Effect of heparin on wound healing
Nydahl et al.	1992	Peroperative anticoagulation with antithrombin or heparin in infrainguinal bypass surgery
Ferrari et al.	1996	Treatment of the heparin-induced thrombosis-thrombocytopenia syndrome by very low dose streptokinase
Edgar et al.	1980	The effect of temperature on formation of fibrin complexes
Breddin	1997	Heparinoids
JPH0532703A (ja)	1993-02-09	低分子量ヘパリン誘導体の製造法
Mastacchi et al.	1986	Heparin structural modifications and human platelet aggregation